| 3.19 0.07 (2.24%) | 09-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.09 | 1-year : | 4.5 |
| Resists | First : | 3.5 | Second : | 3.85 |
| Pivot price | 3.36  |
|||
| Supports | First : | 2.93 | Second : | 2.43 |
| MAs | MA(5) : | 3.11 |
MA(20) : | 3.41 |
| MA(100) : | 3.27 |
MA(250) : | 3.78 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 23.6 |
D(3) : | 18.6 |
| RSI | RSI(14): 45.7 |
|||
| 52-week | High : | 6.94 | Low : | 2.67 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PRME ] has closed above bottom band by 31.6%. Bollinger Bands are 0.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.27 - 3.3 | 3.3 - 3.31 |
| Low: | 3.06 - 3.08 | 3.08 - 3.1 |
| Close: | 3.16 - 3.2 | 3.2 - 3.22 |
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
Thu, 17 Sep 2026
Prime Medicine (NASDAQ:PRME): What's Behind Its Sudden Share Price Jump? - Kalkine Media
Thu, 17 Sep 2026
Prime Medicine (NASDAQ:PRME) Shares Up 11.8% - Should You Buy? - MarketBeat
Wed, 16 Sep 2026
PRME: Prime Editing advances gene editing with broad clinical programs and pivotal data expected in 2027 - TradingView
Tue, 15 Sep 2026
PRME: Prime Editing advances versatile gene therapies with strong clinical and financial momentum - TradingView
Thu, 03 Sep 2026
A gene-editing company sets three September conference appearances - Stock Titan
Thu, 03 Sep 2026
Prime Medicine to Participate in Upcoming Investor Conferences - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 181 (M) |
| Held by Insiders | 1.1225e+008 (%) |
| Held by Institutions | 23.6 (%) |
| Shares Short | 33,540 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.8912e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 750.8 % |
| Return on Equity (ttm) | -46.6 % |
| Qtrly Rev. Growth | 4.07e+006 % |
| Gross Profit (p.s.) | 1.48 |
| Sales Per Share | -158.85 |
| EBITDA (p.s.) | -6.04809e+007 |
| Qtrly Earnings Growth | -1.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -156 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 34.07 |
| Dividend | 0 |
| Forward Dividend | 3.502e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|